Home / Clinical Guideline Hubs / Chapter 5.5
Section 5 — General NICU Care / Supportive Care Verify against local policy v1.0 · July 2026 Baylor Ed. 33 cross-checked Sept 2026

Chapter 5.5 — Immunizations & RSV Prophylaxis

The golden rule — immunize preterm infants by chronological (not corrected) age at full dose — plus hepatitis B at birth and RSV prevention (nirsevimab/palivizumab) — built on West Midlands Neonatal Guidelines 2025–28, AAP/ACIP and national immunization schedules

Educational guideline — verify locally. Immunization schedules, RSV-prophylaxis products, and eligibility differ by country and change over time; verify against your current national schedule and local policy. Does not replace attending judgment.
BEDSIDE ACTION BOX
Open the Immunization Learning Module Interactive guidelines, question bank with explanations, flashcards, quick-reference tables, and a NeoSummary.

1. Overview

Overview

Preterm and NICU infants are at higher risk from vaccine-preventable infections, yet are frequently under-immunized because of misplaced caution. The core principle is simple and high-yield: vaccinate on time by chronological age at full dose. Alongside routine immunizations, specific programs protect newborns — the hepatitis B birth dose to prevent perinatal transmission, and RSV prevention (long-acting monoclonal antibodies and maternal vaccination) to prevent severe bronchiolitis.

Why This Topic Matters

Delaying or reducing vaccines in preterm infants leaves the highest-risk babies unprotected. RSV is a leading cause of infant hospitalization, and effective prevention now exists. Getting timing, dose, and eligibility right prevents serious, avoidable disease.

2. Who This Guideline Applies To

Scope
  • Preterm and term NICU infants reaching immunization age, and infants eligible for hepatitis B birth dose or RSV prophylaxis.
  • Discharge planning teams ensuring immunizations are up to date.
  • Cross-references: preterm discharge/follow-up (2.5), BPD/chronic lung disease (6.2), and congenital infections/hepatitis B (8.3/8.6).

3. Key Definitions

TermDefinition
Chronological ageActual age since birth — used for immunization timing.
Corrected ageAge adjusted for prematurity — NOT used for immunization timing.
Hepatitis B birth doseVaccine (± HBIG) given soon after birth to prevent perinatal HBV transmission.
NirsevimabLong-acting anti-RSV monoclonal antibody for infants in their first RSV season.
PalivizumabMonthly anti-RSV monoclonal antibody for selected high-risk infants (per local criteria).

4. The Golden Rule

Chronological Age, Full Dose, On Time
  • Immunize according to chronological age — a baby born at 26 weeks receives their primary immunizations at the same postnatal age (e.g., 8 weeks) as a term baby.
  • Give the full standard dose — do not reduce or split doses for prematurity/low weight.
  • Do not delay for being in hospital — vaccinate stable inpatients on schedule.
  • Follow the current national schedule for which vaccines are due (e.g., DTaP/IPV/Hib/HepB combinations, pneumococcal, meningococcal, rotavirus per local timing/eligibility).
  • Rotavirus has hard age limits and is the one vaccine you can miss permanently. Baylor Ed. 33: give it at discharge if the infant meets the age criteria — the first dose between 6 and 14 weeks of age, subsequent doses at 4-week intervals, and the last dose no later than 8 months 0 days. RotaTeq is a 3-dose and Rotarix a 2-dose oral regimen. The Rotarix applicator contains latex — do not give it to an infant at risk of latex allergy, such as one with a neural tube defect. It can be given by gastrostomy tube in an infant who does not feed orally.

5. Hepatitis B at Birth

Prevent Perinatal Transmission
  • Give the hepatitis B vaccine birth dose promptly to infants of HBsAg-positive or unknown-status mothers; add hepatitis B immunoglobulin (HBIG) for exposed infants per policy.
  • For very-low-birth-weight infants of HBsAg-positive mothers, follow schedule-specific rules (the birth dose may not count toward the primary series in some schedules) — verify locally.
  • Complete the hepatitis B series and arrange post-vaccination serology testing where indicated.

6. Preterm-Specific Considerations

Practical Points
  • Apnea/bradycardia monitoring: the most immature/ELBW or clinically unstable infants may have cardiorespiratory events after their first immunizations — give in a monitored setting per local policy; this is not a reason to withhold vaccines.
  • Ensure catch-up if any doses were missed; maintain accurate records.
  • Household/caregiver immunization (e.g., pertussis, influenza, COVID as applicable) provides "cocooning" protection.

7. RSV Prophylaxis

Prevent Severe Bronchiolitis
  • Nirsevimab — a single long-acting monoclonal antibody for infants entering their first RSV season (and some high-risk infants entering a second season), per national programs.
  • Palivizumab — monthly during the RSV season for selected high-risk infants (e.g., certain preterm infants, chronic lung disease, hemodynamically significant CHD) per local eligibility criteria.
  • Maternal RSV vaccination in pregnancy provides passive protection to the newborn (an alternative/complement per policy).
  • Eligibility, product choice, and timing differ by country and season — verify against the current program.
The doses and the decision points (Baylor Ed. 33)
  • Nirsevimab, first season, under 8 months: 50 mg IM below 5 kg, 100 mg IM at 5 kg or more — one dose per season, protecting for about 5 months and cutting RSV lower respiratory tract infection and hospitalization by 75–80%.
  • Maternal vaccination changes eligibility: an infant born 14 or more days after the parent received RSVpreF is not routinely eligible; one born within 14 days of that dose is. Nirsevimab may still be given on clinical judgement when the parent is immunocompromised or has HIV and may not have mounted or transferred antibody, after cardiopulmonary bypass or ECMO has stripped maternal antibody, or when RSV risk is substantially raised — haemodynamically significant congenital heart disease, or an ICU stay leaving the infant on oxygen at discharge.
  • Timing: born during the season — give in the first week of life, before discharge or at the first outpatient visit. Preterm or a prolonged birth hospitalization — shortly before or promptly after discharge.
  • Second season, 8–19 months with chronic lung disease needing diuretics, chronic steroids or oxygen within the past 6 months, severe immunocompromise, cystic fibrosis with severe lung disease or weight-for-length below the 10th percentile, or American Indian and Alaska Native children: 200 mg IM, given as two separate 100 mg injections at one time.
  • Re-dose after cardiopulmonary bypass, as soon as the infant is stable: first season — within 90 days of the last dose, 50 mg below 5 kg or 100 mg above; beyond 90 days, 50 mg at any weight. Second season — 200 mg within 90 days, 100 mg beyond.
  • Palivizumab: 15 mg/kg IM every 30 days, maximum 5 doses, started 2–3 days before NICU discharge or promptly after. Stop it for the season after any breakthrough RSV hospitalization — the chance of a second admission in the same season is under 0.5%. It is not recommended to prevent nosocomial RSV. If fewer than 5 palivizumab doses were given, nirsevimab may follow at least 30 days after the last dose, with no further palivizumab.
  • Practical points: there is no minimum age for nirsevimab; it can be co-administered with other vaccines; no RSV testing is needed beforehand and it is given regardless of prior RSV infection; moderate or severe illness is a reason to wait for recovery. In the US the season runs October to March, peaking December to February, with the official start and end set locally. RSV survives hours on surfaces and 30 minutes or more on hands.

8. Immunization Planning Algorithm

1
At birth
Give hepatitis B birth dose (± HBIG) for at-risk infants; record maternal status.
2
Track chronological age
Schedule primary immunizations by chronological age at full dose — do not correct or reduce.
3
Vaccinate on time (even inpatient)
Give due vaccines to stable infants; monitor the most preterm for apnea/bradycardia per policy.
4
Assess RSV eligibility
Nirsevimab/palivizumab per local criteria and season; note maternal RSV vaccination status.
5
Discharge check & catch-up
Confirm immunizations up to date; arrange catch-up and community continuation; counsel on caregiver vaccination.
6
⚠ Do-not-miss
Under-immunizing preterm infants (correcting age/reducing dose); missed hepatitis B birth dose; and missed RSV-prophylaxis eligibility.

9. Monitoring & Records

ItemDetail
Immunization recordDoses given by chronological age; catch-up plan.
Post-immunization observationApnea/bradycardia monitoring in the most preterm per policy.
Hepatitis BBirth dose/HBIG given; series completed; serology if indicated.
RSV prophylaxisEligibility, product, and timing documented.
Discharge/community handoverUp-to-date status communicated to GP/community team.

10. Precautions

Safety Cautions
  • Never correct age or reduce the dose for prematurity — immunize by chronological age at full dose.
  • Do not withhold vaccines simply because an infant is small, preterm, or an inpatient (if stable).
  • Monitor the most immature infants for post-immunization apnea/bradycardia.
  • Verify current national schedule, RSV product/eligibility, and hepatitis B rules (these change).
  • Apply usual contraindications/precautions (e.g., acute severe illness — defer briefly, don't cancel).

11. Escalation & Family Support

Family-Centered Communication
  • "Premature babies need their vaccines on time — at the same age as any baby, at the full dose — because they're more vulnerable to these infections."
  • "We may also offer protection against RSV, a common cause of serious chest infections in babies. Vaccinating those around your baby helps too."

12. Key Pearls

High-Value Clinical Pearls
  • Immunize preterm infants by chronological age, at full dose, on time — never correct or reduce.
  • Don't withhold vaccines for prematurity, low weight, or inpatient status (if stable).
  • Hepatitis B birth dose (± HBIG) for at-risk infants; VLBW HBsAg-exposed have schedule-specific rules.
  • RSV prevention: nirsevimab for first-season infants; palivizumab for selected high-risk; maternal vaccination.
  • Monitor the most preterm for post-immunization apnea/bradycardia.
  • Encourage caregiver immunization ("cocooning").

13. Common Mistakes to Avoid

MistakeWhy it harmsBetter practice
Using corrected age.Delayed protection.Immunize by chronological age.
Reducing/splitting doses.Under-immunization.Full standard dose.
Withholding in NICU.High-risk infants unprotected.Vaccinate stable inpatients on time.
Missing hepatitis B birth dose.Perinatal HBV transmission.Give promptly (± HBIG) for at-risk.
Missing RSV eligibility.Preventable bronchiolitis.Check nirsevimab/palivizumab criteria.

14. Board-Style High-Yield Summary

Key Takeaways
  • Golden rule: immunize preterm infants by chronological age, at full dose, on schedule — never correct or reduce.
  • Do not withhold vaccines for prematurity/low weight/inpatient status (if stable).
  • Hepatitis B birth dose (± HBIG) for at-risk infants; VLBW HBsAg-exposed follow schedule-specific rules.
  • RSV prevention: nirsevimab (first season), palivizumab (selected high-risk), and/or maternal RSV vaccination.
  • Monitor the most preterm/unstable for post-immunization apnea/bradycardia.
  • Verify the current national schedule and RSV program; encourage caregiver "cocooning".

15. References

Back to Clinical Guideline Hubs